Invivyd's PEMGARDA Commercially Available In U.S. For Pre-Exposure Prophylaxis Of COVID-19 In Certain Adults And Adolescents With Moderate-To-Severe Immune Compromise
Portfolio Pulse from Benzinga Newsdesk
Invivyd's PEMGARD is now commercially available in the U.S. for pre-exposure prophylaxis of COVID-19 in certain adults and adolescents with moderate-to-severe immune compromise. This marks a significant step in providing additional protection against COVID-19 for individuals with compromised immune systems.
April 04, 2024 | 8:03 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Invivyd's release of PEMGARD in the U.S. for pre-exposure prophylaxis of COVID-19 in immune-compromised individuals could positively impact its stock due to the potential market demand.
The commercial availability of PEMGARD in the U.S. represents a significant advancement in Invivyd's product portfolio, potentially increasing its market share and revenue. Given the ongoing need for COVID-19 prophylactic solutions, especially among vulnerable populations, this launch could lead to increased investor confidence and a positive short-term impact on IVVD's stock price.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100